RxDoctor Payments Data

Kayleigh Geiser

Family · Brookville, INNPI 1104492867

Payments from drug & device makers

$1,957in general payments, 2019–2025

Across 129 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$394
  • AbbVie$306
  • Lilly USA, LLC$266
  • AstraZeneca$105
  • Amgen$96
  • Sunovion Pharmaceuticals Inc.$82
  • plus $708 from 22 others

What the payments were for

  • Food & beverage$1,957100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,957 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$74,149
Medicare patients
250
Services billed
1,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$166,951
EliquisApixaban93$78,323
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$54,587
JardianceEmpagliflozin31$46,884
JanuviaSitagliptin Phosphate19$30,743
Breo ElliptaFluticasone/Vilanterol55$24,623
MounjaroTirzepatide23$23,993
RexultiBrexpiprazole14$20,821
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$17,139
LinzessLinaclotide20$11,542
Synjardy XrEmpagliflozin/Metformin Hcl11$10,390
Tresiba Flextouch U-100Insulin Degludec16$9,548
MyrbetriqMirabegron17$8,502
Novolog FlexpenInsulin Aspart15$4,594
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$394$166,951141 claims
PfizerEliquis, Paxlovid$78$81,027117 claims
MerckJanuvia$37$30,74319 claims
Lilly USA, LLCMounjaro$266$23,99323 claims
Otsuka America Pharmaceutical, Inc.Rexulti$71$20,82114 claims
AstraZenecaBreztri Aerosphere, Symbicort$105$19,58338 claims
AbbVieLinzess, Synthroid$306$15,61469 claims
Astellas Pharma US IncMyrbetriq$15$8,50217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Brookville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →